An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
Kezar Life Sciences, Inc. (NASDAQ: KZR) has granted a nonqualified stock option to an employee for 100,000 shares at an exercise price of $15.44, aligning with the stock's closing price on April 13, 2022. This option is part of an inducement award critical to the individual’s employment and will vest over four years, with 25% vesting on the first anniversary, followed by monthly vesting. Kezar specializes in developing innovative treatments for immune-mediated and oncologic disorders, focusing on first-in-class therapies like Zetomipzomib and KZR-261.
Positive
None.
Negative
None.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the company’s Board of Directors has granted one employee a nonqualified stock option to purchase 100,000 shares of its common stock with an exercise price of $15.44 per share, which is equal to the closing price of Kezar’s common stock on April 13, 2022, the grant date of the award. This grant was part of an inducement award material to the individual’s employment with Kezar, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option will vest over a four-year period, with 25% of the option vesting on the first anniversary of the employee’s date of hire, and 1/48th of the option vesting monthly thereafter, subject to the employee’s continued employment with Kezar on such vesting dates. The option is subject to the terms and conditions of Kezar’s 2022 Inducement Plan and the stock option agreement covering the grant.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in Phase 2 clinical trials in lupus nephritis, dermatomyositis and polymyositis. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.
